



(43) International Publication Date
26 May 2016 (26.05.2016)

(10) International Publication Number
WO 2016/081826 A2

- (51) International Patent Classification: Not classified
- (21) International Application Number:
PCT/US2015/061834
- (22) International Filing Date:
20 November 2015 (20.11.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/082,895 21 November 2014 (21.11.2014) US
62/131,441 11 March 2015 (11.03.2015) US
62/243,374 19 October 2015 (19.10.2015) US
- (71) Applicant: OPHIREX, INC [US/US]; 5643 Paradise Drive #2, Corte Madera, CA 94925 (US).
- (72) Inventor: LEWIN, Matthew, R.; 5643 Paradise Drive #2, Corte Madera, CA 94925 (US).
- (74) Agent: COLEMAN, Henry, D.; Cosud Intellectual Property Solutions, P.C., 714 Colorado Avenue, Bridgeport, CT 06605-1601 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) Title: ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITS

(57) Abstract: The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLA₂ inhibitor (sPLA₂ or PLA₂ inhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without anti-venom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.



WO 2016/081826 A2